💡 Here's the latest update from Science42: #DORA, an advanced AI driven tool designed to streamline the process of creating documents and writing #academicpapers. Check out the latest tutorial: How to generate a review paper
Insilico Medicine
Biotechnology Research
Boston, Massachusetts 57,282 followers
#insilicomeds, #drugdiscovery, #ai, #GANs, #GANs-RL, #DL #aging, #longevity
About us
Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
- Website
-
http://www.Insilico.com
External link for Insilico Medicine
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2014
- Specialties
- artificial intelligence, deep learning, reinforcement learning, drug discovery, aging research, longevity, biomarker development, Generative adversarial networks, GANs, and GANs-RL
Locations
-
Primary
1000 Massachusetts Ave
Boston, Massachusetts 02138, US
-
345 Park Ave S
New York, NY 10010, US
-
1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok
Unit 307A, Core Building 1
New Territories, HK
Employees at Insilico Medicine
Updates
-
“Often the most difficult step when it comes to writing is starting the process. Something that I experienced first-hand as a graduate student when I was tasked with writing numerous grants, papers, and reports,” said Petrina Kamya, Ph.D. “We developed Science42: #DORA to help eliminate that debilitating barrier to writing #scientificdocuments.” Insilico’s developers collaborated with researchers at the University of Copenhagen to submit a paper on #medRxiv. The paper drafted by DORA and later manually curated and extended, performs a comparative study about radiotherapy outcomes across brain tumor types, namely glioblastoma multiform and low-grade gliomas based on radiotherapy phenotype and expression data from 32 #cancerdatasets. Read the full release from Genetic Engineering & Biotechnology News https://lnkd.in/eeWDner8
-
Longevity: Anti-aging drugs, watch out, here we come… In October 2023, researchers from the University of Oslo and, the University of Chicago Pritzker School of Medicine published an article in the journal Aging Cell, where they used Insilico Medicine’s PandaOmics (see above) to identify 22 dual-purpose target candidates for anti-ageing and anti-cancer treatment. One candidate, histone demethylase KDM1A, has since been shown to significantly extend lifespan in an ageing research animal model and has anti-cancer activities in clinical studies in colorectal and triple-negative breast cancer. Read the full piece today: https://bit.ly/4cZTdPz
-
Our mission is to develop and promote open source cutting-edge #generativeAI technologies for environmental #sustainability. Hear more from our team here:
-
Get ready for the highly requested #AI in #DrugDiscovery Conference this October 2024 in the United States. In the interim since our last gathering in March 2024 in the UK, the industry has achieved a groundbreaking milestone – the first wholly AI-discovered and designed drug is now undergoing Phase 2 clinical trials. Four compelling reasons as to why you can't miss out: -Gain insights from leading biotechs and big pharma on drug target selection -Explore neural networks with a focus on digital twins, new drug designs and in-silico modelling to expand your portfolio -Get the latest insights on the benefits of machine learning from molecule design to clinical trial selection, along with crucial patient-centric considerations. -Discuss best use and potential impact of Generative AI in light of the launch of Chat GPT See the full agenda, and learn more about Petrina’s presentation here: https://bit.ly/3MlvxtS
-
-
Insilico Medicine reposted this
Prof. Lykke Sylow presents on Preserving muscle mass for healthy aging: Old tricks and new targets today and talked about one of the hottest therapeutic targets TNIK. #ARDD2024 Alex Zhavoronkov Morten Scheibye-Knudsen Daniela Bakula Insilico Medicine
-
-
Insilico Medicine reposted this
🌟 Meet Insilico Medicine’s team at Aging Research & Drug Discovery Meeting! Our team is on-site and ready to showcase the power of our Pharma.AI platform! Join us for live demo where you can explore how our cutting-edge AI technologies are transforming drug discovery and aging research. This is a rare opportunity to connect directly with our experts, try out our platform, and see firsthand how Pharma.AI can accelerate your research. Let’s connect and drive the future of healthcare together! Alex Zhavoronkov Alex Aliper Frank Pun Jan Szollos, MBA Aisyah S. Fedor Galkin Stephanie Tsang PandaOmics Chemistry42 Precious3GPT inClinico #ARDD2024 #InsilicoMedicine #PharmaAI #agingresearch #drugdiscovery #AIinhealthcare
-
-
Insilico Medicine made the news this year as well with a publication around its leading pipeline candidate INS018_055, a #small-molecule inhibitor of the novel antifibrotic target TRAF2- and NCK-interacting kinase (TNIK), which was also identified using the company’s end-to-end platform2. The compound is currently in a #phase2 trial for idiopathic pulmonary #fibrosis—an indication for which new #therapies are greatly needed and that has historically seen many failures in drug development. While AI-designed antibodies are yet to reach the clinic, the outcomes from trials for small molecules such as INS018_055 that are now in progress will be closely watched to understand whether #AI is able to accelerate not just the discovery of drug candidates, but also the identification of those that are capable of succeeding in the clinic where others have not in the past. Read more from Nature here: https://bit.ly/475XY8D
-
-
Insilico Medicine reposted this
CEO @Institute for Healthier Living Abu Dhabi | Staff Physician Former Chair, Preventive Medicine @Cleveland Clinic Abu Dhabi | Award-winning International Speaker Healthy Longevity Precision Lifestyle Medicine
Looking forward to August 28th when I will share insights from our work at Institute for Healthier Living Abu Dhabi at the 11th #ARDD2024 Meeting. With a stellar lineup of speakers and the XPRIZE Healthspan Team Summit, expect groundbreaking discussions that will shape the future of healthy aging. Stay tuned! #ARDD2024 #UniversityofCopenhagen #Longevity #InstituteforhealthierlivingAD #IHLAD #healthcare #precisionlifestylemedicine #abudhabi #healthylongevity #XPRIZEHealthspan
-
-
✈ The Insilico Team looks forward to next week in #Copenhagen at the 11th Aging Research & Drug Discovery Meeting ⚡ Don't miss out on presentations led by Alex Zhavoronkov, Fedor Galkin Precious3GPT, and Frank Pun. Be sure to meet our Pharma.AI team, Jan Szollos, MBA and Aisyah S. (https://lnkd.in/e7Y3E-Zn) to discuss all things: Science42: #DORA https://lnkd.in/dEPshUTw Generative Biologics Chemistry42 PandaOmics #PandaOmicsBox ... and more! Here's more information about next week's event: https://agingpharma.org/
Dermatologist | Founder & Formulator of Dr Liv Skincare and Supplements | Entrepreneur | Author| Medical Social Media Personality | Skin Longevity | Ex-Researcher | Speaker | Advisor | AI
🚀This conference is truly the epicenter of the latest advancements in #longevity I’m beyond excited to attend the Aging Research & Drug Discovery Meeting at the University of Copenhagen (Københavns Universitet) for the second year in a row! 🚀 With just some days to go, #ARDD2024 was quick completely sold out, including all sponsorship tiers—showcasing the unstoppable momentum in the longevity and aging research fields. 💯 absolutely looking forward catching up with Evelyne Bischof, MD, PhD , who is leading the pivotal #LongevityMedicine track. Evelyne’s work is crucial in integrating cutting-edge geroscience and AI into clinical practice, with a strong focus on extending healthspan and reversing biological aging. The event will kick off with the Healthspan XPRIZE Summit led by the Jamie Justice, Ph.D. setting the stage for a week of innovation. The Longevity Education Hub is integrating the conference materials into its curriculum, ensuring that this knowledge reaches the next generation of leaders in the field. The Longevity Biotechnology Association is also on board, supporting the event and organizing exciting side activities. Looking forward for seeing major breakthroughs presented by leading #pharma and #biotech companies focused on metabolism, #neuro, #muscle wasting, and #aging-related diseases. A huge thank you to Alex Zhavoronkov Ph.D., for his visionary leadership in the field. As the founder and CEO of Insilico Medicine , Alex has been pioneering the use of #AI in #drug discovery and aging research, driving forward the advancements that make events like #ARDD2024 so impactful. Huge kudos to the fantastic team, including Morten Scheibye-Knudsen Daniela Bakula Alex Zhavoronkov and Evelyne Bischof, MD, PhD for making this the premier event in the field. 🚀🚀🚀🚀🚀🚀🚀🚀🚀 Can’t wait to connect with everyone in Copenhagen and see what new breakthroughs are on the horizon! 🌟 #ARDD #Longevity #Biotech #AgingResearch #XPRIZE #Innovation #pharma #venturecapital I LongeVC Brilliant Minds BioInnovation Institute Healthspan Capital Altos Labs True Diagnostics™ Haut.AI
-